Actinium Pharmaceuticals, Inc.
ATNM
AMEX·Healthcare·Biotechnology·Mkt cap $32.3M
$1.03
▼ -1.44%
P/E
1.45
Mkt Cap
$32.3M
52-Wk Range
$0.74–$1.74
52-Week Range
$0.74 - $1.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 35.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
-4.6% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ATNM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 7, 2026
Reported EPS of $0.89 vs $0.89 consensus (0.0% surprise). Revenue of $35.0M vs $35.0M expected (0.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$35.0M
Margins · last 2Q
Gross
0.0%
Operating
78.8%
Profit
79.7%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Stephens · Mar 31, 2026
vs Industry
How ATNM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.